Skip to main content
Clinical Cardiology logoLink to Clinical Cardiology
. 2009 Feb 3;23(7):530–534. doi: 10.1002/clc.4960230712

Failure of magnesium to protect isolated cardiomyocytes from effects of hypoxia or metabolic poisoning

Mark M Gallagher 1,, Ashley P Allshire 1
PMCID: PMC6655034  PMID: 10894442

Abstract

Background: MgSO 4 appears to reduce infarct size in animal models of myocardial infarction‐reperfusion, but only if given before reperfusion. The mechanisms underlying this effect have not been established, nor has the discrepancy between these results and the lack of efficacy in the Fourth International Study of Infarct Survival (ISIS‐4) been explained.

Hypothesis: The study was undertaken to examine the hypothesis that Mg 2+ protects myocardium threatened by ischemia.

Methods: We studied the effects of extracellular magnesium [Mg2+ ] e at 0.6 and 1.8 mmol/l on isolated myocytes exposed to 2.5 mmol/l NaCN + 5 mmol/l 2‐deoxyglucose or to profound hypoxia.Results: Nonpaced cells shortened at a mean of 8.8 min after onset of metabolic inhibition in [Mg 2+] e =1.8 mmol/l, 9.6 min in [Mg 2+]s e = 0.6 mmol/l (not significant). Paced cells shortened after 9.5 min in [Mg 2+] e = 1.8 mmol/l, 10.2 min at [Mg 2+ ] e = 0.6 mmol/l. On washout of inhibitors, 93% of cells underwent hypercontracture at [Mg 2+ ] e = 1.8 mmol/l, 94.8% at [Mg 2+ ] e = 0.6 mmol/l. During hypoxia, nonpaced cells in [Mg 2+ ] e = 1.8 mmol/l shortened after 67 ± 11 min compared with 62.5 ± 28 min at [Mg 2+ ] e = 0.6 mmol/l. Paced cells shortened after 25.8 ± 12.9 min at [Mg 2+] e = 1.8 mmol/l and after 28.7 ± 13.6 min at [Mg 2+ ] e = 0.6 mmol/l. Although there was a trend toward longer survival at higher [Mg 2+ ] e, the difference was small and not significant (p > 0.05, Student's paired t‐test).

Conclusion: We find no evidence to support the hypothesis that [Mg 2+ ] protects myocardium threatened by ischemia.This is consistent with clinical data but contradicts data from animal experiments.

Keywords: magnesium, ischemic myocardium, myocardial infarction, cytoprotection, contracture

Full Text

The Full Text of this article is available as a PDF (515.0 KB).

References

  • 1. Muller JE, Stone PH, Turi ZG, Rutherford JD, Czeisler CA, Parker C, Poole WK, Passamani E, Roberts R, Robertson T, Sobel BE, Willerson JT, Braunwald E, MILIS Study Group : Orcadian variation in the frequency of onset of acute myocardial infarction. N Engl J Med 1985; 313: 1315–1322 [DOI] [PubMed] [Google Scholar]
  • 2. Willich SN, Linderer T, Wegscheider K, Leizorovich A, Alamercery I, Schroder R, ISAM Study Group : Increased morning incidence of myocardial infarction in the ISAM study: Absence with prior b̃‐adrenergic blockade. Circulation 1989; 80: 853–858 [DOI] [PubMed] [Google Scholar]
  • 3. Willich SN, Levy D, Rocco MB, Tofler GF, Stone PH, Muller JE: Circadian variation in the incidence of sudden cardiac death in the Framingham heart study population. Am J Cardiol 1987; 60: 801–806 [DOI] [PubMed] [Google Scholar]
  • 4. Anderson LT, Sigurd B, Hansen JF: Verapamil and circadian variation of sudden cardiac death. Am Heart J 1996; 131: 409–410 [DOI] [PubMed] [Google Scholar]
  • 5. Rocco MB, Barry J, Campbell S, Nabel E, Cook EF, Goldman L, Selwyn AP: Circadian variation of transient myocardial ischemia in patients with coronary artery disease. Circulation 1987; 75: 395–400 [DOI] [PubMed] [Google Scholar]
  • 6. Willich AN, Lowel H, Lewis M, Arntz R, Baur R, Winther K, Keil U, Schroder R, TRIMM Study Group : Association of wake time and the onset of myocardial infarction. Circulation 1991; 84 (suppl VI): VI62–VI67 [PubMed] [Google Scholar]
  • 7. Millar‐Craig MW, Bishop CN, Raftery EB: Circadian variation of blood‐pressure. Lancet 1978; 1: 795–797 [DOI] [PubMed] [Google Scholar]
  • 8. Pratt CM, McMahon RP, Goldstein S, Pepine CJ, Andrews TC, Dyrda I, Frishman WH, Geller NL, Hill JA, Morgan NA, Stone PH, Knatterud GL, Sopko G, Conti CR: Comparison of subgroups assigned to medical regimens used to suppress cardiac ischemia. Am J Cardiol 1996; 77: 1302–1309 [DOI] [PubMed] [Google Scholar]
  • 9. Frishman WH, Rosenberg A, Katz B: Calcium antagonists in the management of systemic hypertension: The impact of sustained‐release drug‐delivery systems. Coron Artery Dis 1994; 5: 4–12 [DOI] [PubMed] [Google Scholar]
  • 10. Anwar YA, White WB: Chronotherapeutics for cardiovascular disease. Drugs 1998; 55: 631–643 [DOI] [PubMed] [Google Scholar]
  • 11. Frishman WH, Glasser S, Stone P, Deedwania PC, Johnson M, Fakouhi TD: Comparison of controlled‐onset, extended‐release verapamil with amlodipine and amlodipine plus atenolol on exercise performance and ambulatory ischemia in patients with chronic stable angina pectoris. Am J Cardiol 1999; 83: 507–514 [DOI] [PubMed] [Google Scholar]
  • 12. White WB, Black HR, Weber MA, Elliott WJ, Bryzinski B, Fakouhi TD: Comparison of effects of controlled onset extended release verapamil at bedtime and nifedipine gastrointestinal therapeutic system on arising on early morning blood pressure, heart rate, and the heart rate‐blood pressure product. Am J Cardiol 1998; 81: 424–431 [DOI] [PubMed] [Google Scholar]
  • 13. Andrews TC, Fenton T, Toyosaki N, Glasser SP, Young PM, MacCallum G, Gibson RS, Shook TL, Stone PH: Subsets of ambulatory myocardial ischemia based on heart rate activity, circadian distribution and response to anti‐ischemic medication. Circulation 1993; 88: 92–100 [DOI] [PubMed] [Google Scholar]
  • 14. Chierchia S, Gallino A, Smith G, Deanfield J, Morgan M, Croom M, Maseri A: Role of heart rate in pathophysiology of chronic stable angina. Lancet 1984; 2: 1352–1357 [DOI] [PubMed] [Google Scholar]
  • 15. Palatini P, Julius S: HR and cardiovascular risk. J Hypertens 1997; 15: 3–17 [DOI] [PubMed] [Google Scholar]
  • 16. Gillman MW, Kannel WB, Belanger A, D'Agostino RB: Influence of heart rate on mortality among persons with hypertension: The Framingham study. Am Heart J 1993; 125: 1148–1154 [DOI] [PubMed] [Google Scholar]
  • 17. Levy RL, White PD, Stroud WD, Hilman CC: Transient tachycardia: Prognostic significance alone and in association with transient hypertension. J Am Med Assoc 1945; 129: 585–588 [Google Scholar]
  • 18. Pratt CM, McMahon RP, Goldstein S, Pepine CJ, Andrews TC, Dyrda I, Frishman WH, Geller NL, Hill JA, Morgan NA, Stone PH, Knatterud GL, Sopko G, Conti CR: Comparison of subgroups assigned to medical regimens used to suppress cardiac ischemia (the asymptomatic cardiac ischemia pilot study). Am J Cardiol 1996; 77: 1302–1309 [DOI] [PubMed] [Google Scholar]
  • 19. Quyyumi AA, Panza JA, Diodati JG, Lakatos E, Epstein SE: Circadian variation in ischemic threshold. A mechanism underlying the circadian variation in ischemic events. Circulation 1992; 86: 22–28 [DOI] [PubMed] [Google Scholar]
  • 20. Black HR, Elliott WJ, Neaton JD, Grandits G, Grambsch P, Grimm RH, Hansson L, Lacouciere Y: Rationale and design for the controlled onset verapamil investigation of cardiovascular endpoints (CONVINCE) trial. Control Clin Trials 1998; 19: 370–390 [DOI] [PubMed] [Google Scholar]

Articles from Clinical Cardiology are provided here courtesy of Wiley

RESOURCES